HLS Therapeutics (TSE:HLS) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of HLS Therapeutics (TSE:HLS) from a hold rating to a moderate buy rating in a report published on Thursday morning, MarketBeat reports. They currently have C$6.00 price objective on the stock, up from their prior price objective of C$5.00.

HLS Therapeutics Price Performance

HLS Therapeutics stock opened at C$5.22 on Thursday. The company’s 50 day simple moving average is C$4.96 and its 200-day simple moving average is C$4.61. The company has a market capitalization of C$116.13 million, a price-to-earnings ratio of -5.23 and a beta of 1.07. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.